<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Rx Times Pharmacy Magazine&#187; GlaxoSmithKline</title>
	<atom:link href="http://www.rxtimes.com/tag/glaxosmithkline/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.rxtimes.com</link>
	<description>Pharmacy news, jobs, continuing education, community and more.</description>
	<lastBuildDate>Mon, 09 Jan 2012 03:45:59 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.2.1</generator>
		<item>
		<title>Abbott Expands Agreement with GSK for an Additional Investigational Cancer Immunotherapy Antigen</title>
		<link>http://www.rxtimes.com/abbott-expands-agreement-with-gsk-for-an-additional-investigational-cancer-immunotherapy-antigen/</link>
		<comments>http://www.rxtimes.com/abbott-expands-agreement-with-gsk-for-an-additional-investigational-cancer-immunotherapy-antigen/#comments</comments>
		<pubDate>Mon, 28 Nov 2011 23:13:18 +0000</pubDate>
		<dc:creator>Rx Times</dc:creator>
				<category><![CDATA[FDA+Drugs+Regulatory]]></category>
		<category><![CDATA[Abbott]]></category>
		<category><![CDATA[GlaxoSmithKline]]></category>
		<category><![CDATA[GSK]]></category>

		<guid isPermaLink="false">http://www.rxtimes.com/?p=5644</guid>
		<description><![CDATA[Abbott (NYSE: ABT) announced today that it will expand its existing agreement with GlaxoSmithKline Biologicals S.A. (GSK) to include the development of an additional companion diagnostic test in support of GSK&#8217;s cancer immunotherapy research program. Companion diagnostic tests are designed to identify specific DNA sequences to help guide physicians in determining which patients are more [...]]]></description>
		<wfw:commentRss>http://www.rxtimes.com/abbott-expands-agreement-with-gsk-for-an-additional-investigational-cancer-immunotherapy-antigen/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>FDA Approves Once-A-Day Lamictal(R)XR(TM) as Add-On Epilepsy Therapy for Primary Generalized Tonic-Clonic Seizures</title>
		<link>http://www.rxtimes.com/fda-approves-once-a-day-lamictalrxrtm-as-add-on-epilepsy-therapy-for-primary-generalized-tonic-clonic-seizures/</link>
		<comments>http://www.rxtimes.com/fda-approves-once-a-day-lamictalrxrtm-as-add-on-epilepsy-therapy-for-primary-generalized-tonic-clonic-seizures/#comments</comments>
		<pubDate>Sat, 30 Jan 2010 01:46:59 +0000</pubDate>
		<dc:creator>Staff Writer</dc:creator>
				<category><![CDATA[Pharmacy]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[GlaxoSmithKline]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Lamictal XR]]></category>

		<guid isPermaLink="false">http://www.rxtimes.com/?p=4488</guid>
		<description><![CDATA[GlaxoSmithKline announced today that the U.S. Food and Drug Administration has approved Lamictal®XR™ (lamotrigine) Extended-Release Tablets as once-a-day, add-on therapy for epilepsy in patients ages 13 years and older with primary generalized tonic-clonic seizures.  This is an expanded label, as Lamictal XR is approved for partial onset seizures (with or without secondary generalization) for patients [...]]]></description>
		<wfw:commentRss>http://www.rxtimes.com/fda-approves-once-a-day-lamictalrxrtm-as-add-on-epilepsy-therapy-for-primary-generalized-tonic-clonic-seizures/feed/</wfw:commentRss>
		<slash:comments>2</slash:comments>
		</item>
	</channel>
</rss>

